Women's Health Research Gap Threatens UK Supplement Market Compliance

London, United Kingdom — 23 April 2026

The Centre for Nutraceuticals, based at the University of Westminster, is highlighting a substantial deficit in clinical research involving women, particularly within sports nutrition. Dr. Helena Tiekou Lorinczova and Dr. Stephanie Ho Yi Chan presented key findings at the recent Making Nutraceuticals conference in Coventry, emphasising that while women account for 80% of purchasing decisions in many household categories, their physiological responses to supplements remain largely unstudied. This research gap undermines product efficacy claims and poses a significant risk for brands operating in the UK's burgeoning women's health supplement sector.

Dr. Chan detailed the complexities of researching women due to significant hormonal fluctuations throughout monthly and life cycles. These fluctuations impact nutrient absorption, digestive health, enzyme activity, and the gut microbiome. For example, higher progesterone levels during the luteal phase reduce nutrient absorption, while elevated oestrogen before ovulation improves it. Current clinical trial methodologies often fail to account for these variables, leading to generalised data that may not accurately reflect product performance in female consumers.

To address these challenges, the Centre for Nutraceuticals stratifies clinical trial data based on participants' hormone cycles, allowing for precise analysis of how hormonal status influences absorption and efficacy. This methodology is crucial for understanding the true impact of bioactives like iron, magnesium, and B12, whose absorption can be compromised by factors such as high cortisol levels, a common issue given recent Lumina Intelligence research identifying sleep and stress as key womens' health concerns.

Manufacturers are advised to prioritise highly bioavailable ingredients, utilise smart nutrient pairings, and incorporate biotics to enhance gut health and absorption. Specific dosage recommendations were highlighted: 200-400mg of magnesium for sleep and stress, 1000-2000 IU vitamin D with 90-120mcg K2 for bone health (critical given higher osteoporosis rates in women), and 18-28mg of iron to replenish monthly losses, particularly pertinent for active women.

What this means for United Kingdom

UK brand owners must immediately review their product development and claims substantiation processes for women's health lines. Relying on male-centric or non-sex-stratified data for products marketed to women will invite MHRA scrutiny and consumer distrust. Reformulation windows now exist to integrate highly bioavailable ingredients and functional pairings while setting precise timing recommendations to maximise efficacy. This proactive approach, coupled with investment in female-specific clinical trials or partnerships with research bodies like the Centre for Nutraceuticals, offers a critical competitive advantage, enabling brands to differentiate through genuinely effective, evidence-backed products. Ignoring this gap risks losing market share to more agile, scientifically rigorous competitors and facing potential compliance penalties.

The Centre is actively conducting studies, including one with Gencor on PEA for stress management in female students, and another investigating iron's impact on cognitive performance in female athletes. These studies underscore the industry's need for targeted scientific investment to support product claims effectively.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.